ClinicalTrials.Veeva
Menu

Find clinical trials for Acute Myeloid Leukemia (AML) in Boston, MA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Leukemia
Acute Myeloid Leukemia
Myeloid Leukemia
Myelodysplastic Syndromes
Preleukemia
Syndrome
Cancer

Acute Myeloid Leukemia (AML) trials near Boston, MA, USA:

A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation

The purpose of this study is to determine the clinical benefit of ASP2215 therapy in participants with FMS-like tyrosine kinase (FLT3) mutated acute...

Active, not recruiting
Leukemia, Acute Myeloid (AML)
Drug: MEC (Mitoxantrone, Etoposide, Cytarabine)
Drug: gilteritinib

Phase 3

Astellas
Astellas

Boston, Massachusetts, United States and 125 other locations

Locations recently updated

The main objective of this study is to evaluate the efficacy of venetoclax in combination with azacitidine to improve Overall Survival (OS) in Acute...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Cancer
Drug: Venetoclax
Drug: Azacitidine

Phase 3

AbbVie
AbbVie

Boston, Massachusetts, United States and 164 other locations

CLN-049-001 is a Phase 1, open-label, multicenter, first-in-human trial of CLN-049 in patients with Relapsed/Refractory Acute Myeloid...

Enrolling
Relapsed/Refractory Acute Myeloid Leukemia (AML)
Myelodysplastic Syndrome (MDS)
Drug: CLN-049

Phase 1

Cullinan Therapeutics Inc.

Boston, Massachusetts, United States and 6 other locations

Locations recently updated

to be used in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelodysplastic s...

Enrolling
Relapsed Adult AML
Leukemia, Myeloid, Acute
Drug: Venetoclax Oral Tablet
Drug: Tuspetinib

Phase 1, Phase 2

Aptose Biosciences

Boston, Massachusetts, United States and 33 other locations

The purpose of this study is to determine the recommended Phase 2 dose (RP2D) candidate(s) of bleximenib in combination with AML directed th...

Enrolling
Leukemia, Myeloid, Acute
Drug: Bleximenib
Drug: Daunorubicin or Idarubicin

Phase 1

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Boston, Massachusetts, United States and 30 other locations

The purpose of this Phase I, multicenter, clinical trial is to evaluate the safety of AG-120 and AG-221 when given in combination with standard AML...

Active, not recruiting
Untreated AML
AML Arising From Antecedent Hematologic Disorder (AHD)
Drug: cytarabine
Drug: daunorubicin

Phase 1

Servier
Servier

Boston, Massachusetts, United States and 16 other locations

Anti-tumor Activity of LYT- 200 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML), or with Relaps...

Enrolling
AML, Adult Recurrent
MDS
Drug: Azacitidine
Drug: Decitabine

Phase 1

PureTech Health

Boston, Massachusetts, United States and 10 other locations

This is a Phase 2 study of the study drug, ivosidenib (a mutant IDH1 inhibitor), compared to placebo, given to patients with IDH1-mutant acute...

Begins enrollment in 4 months
Acute Myeloid Leukemia (AML)
Hematopoietic Stem Cell Transplant (HSCT)
Drug: Placebo
Drug: Ivosidenib

Phase 2

Mass General Brigham
Mass General Brigham

Boston, Massachusetts, United States and 1 other location

to venetoclax + azacitidine in adults recently diagnosed with AML who are unable to be treated with intensive chemotherapy.Participants will...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Drug: Pevonedistat
Drug: Venetoclax

Phase 2

Takeda
Takeda

Boston, Massachusetts, United States and 56 other locations

This trial will seek to extend the preliminary findings of efficacy of MBG453 in combination with hypomethylating agents (HMA) by evaluating MBG453 i...

Active, not recruiting
Acute Myeloid Leukemia
Drug: MBG453
Drug: Venetoclax

Phase 2

Novartis
Novartis

Boston, Massachusetts, United States and 27 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems